This article examines the Federal Trade Commission’s evolving use of innovation competition theories of harm in merger review following the adoption of the new 2023 Merger Guidelines. Departing from the traditional antitrust theories of harm, innovation-based enforcement targets mergers that either suppress rivalrous research and development (“R&D”) efforts or extinguish nascent technological competition. This article centers around the life sciences market, which is characterized by i
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 216.73.216.189
Please verify email or join us to access premium content!